Leap Therapeutics (NASDAQ:LPTX) lost 63% in the premarket on Tuesday after the antibody-based drug developer announced that it would not advance its lead candidate, sirexatamab, in Phase 3 studies ...

Leap Therapeutics Inc . (NASDAQ:LPTX) shares have tumbled to a 52-week low, touching down at $0.8 amidst a challenging market environment. With a market capitalization of just $29.89 million ...

Additional updates on the progression free survival data provide a future catalyst, with LPTX planning to provide updates in 2025. LPTX plans to run a phase 3 study of DKN-01 in colorectal cancer ...

Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...

NASDAQ LPTX opened at $0.56 on Thursday. The company has a market capitalization of $21.46 million, a PE ratio of -0.29 and a beta of 0.17. Leap Therapeutics has a twelve month low of $0.51 and a ...

Short interest in Leap Therapeutics Inc (NASDAQ:LPTX) increased during the last reporting period, rising from 2.46M to 3.21M. This put 9.95% of the company's publicly available shares short.

Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...